These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20565339)

  • 1. The challenges of in silico contributions to drug metabolism in lead optimization.
    Vaz RJ; Zamora I; Li Y; Reiling S; Shen J; Cruciani G
    Expert Opin Drug Metab Toxicol; 2010 Jul; 6(7):851-61. PubMed ID: 20565339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico site of metabolism prediction of cytochrome P450-mediated biotransformations.
    Tarcsay Á; Keseru GM
    Expert Opin Drug Metab Toxicol; 2011 Mar; 7(3):299-312. PubMed ID: 21291341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of methods for the prediction of the metabolic sites for CYP3A4-mediated metabolic reactions.
    Zhou D; Afzelius L; Grimm SW; Andersson TB; Zauhar RJ; Zamora I
    Drug Metab Dispos; 2006 Jun; 34(6):976-83. PubMed ID: 16540587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model-based drug discovery: implementation and impact.
    Visser SA; Aurell M; Jones RD; Schuck VJ; Egnell AC; Peters SA; Brynne L; Yates JW; Jansson-Löfmark R; Tan B; Cooke M; Barry ST; Hughes A; Bredberg U
    Drug Discov Today; 2013 Aug; 18(15-16):764-75. PubMed ID: 23726890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of in vitro systems and preclinical data for the prediction of human intestinal first-pass metabolism during drug discovery and preclinical development.
    Karlsson FH; Bouchene S; Hilgendorf C; Dolgos H; Peters SA
    Drug Metab Dispos; 2013 Dec; 41(12):2033-46. PubMed ID: 23918667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitigating permeability-mediated risks in drug discovery.
    Wang J; Skolnik S
    Expert Opin Drug Metab Toxicol; 2010 Feb; 6(2):171-87. PubMed ID: 20064074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elucidating substrate promiscuity in the human cytochrome 3A4.
    Hayes C; Ansbro D; Kontoyianni M
    J Chem Inf Model; 2014 Mar; 54(3):857-69. PubMed ID: 24571781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state.
    Feng B; LaPerle JL; Chang G; Varma MV
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):939-52. PubMed ID: 20433402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural ensemble in computational drug screening.
    Fukunishi Y
    Expert Opin Drug Metab Toxicol; 2010 Jul; 6(7):835-49. PubMed ID: 20465522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of sites of metabolism in a substrate molecule, instanced by carbamazepine oxidation by CYP3A4.
    Yuki H; Honma T; Hata M; Hoshino T
    Bioorg Med Chem; 2012 Jan; 20(2):775-83. PubMed ID: 22197672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in silico Approaches to Study Cytochrome P450-Mediated Interactions.
    Tan BH; Pan Y; Dong AN; Ong CE
    J Pharm Pharm Sci; 2017; 20(1):319-328. PubMed ID: 29145931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of hydrophobic parameters in identifying appropriate pose of CYP substrates in cytochromes.
    Ramesh M; Bharatam PV
    Eur J Med Chem; 2014 Jan; 71():15-23. PubMed ID: 24269512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose Predictions for Drug Design.
    Maurer TS; Smith D; Beaumont K; Di L
    J Med Chem; 2020 Jun; 63(12):6423-6435. PubMed ID: 31913040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of HT-ADME in drug discovery.
    Morgan D
    Bioanalysis; 2011 Nov; 3(21):2385-7. PubMed ID: 22074279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting drug metabolism: experiment and/or computation?
    Kirchmair J; Göller AH; Lang D; Kunze J; Testa B; Wilson ID; Glen RC; Schneider G
    Nat Rev Drug Discov; 2015 Jun; 14(6):387-404. PubMed ID: 25907346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SOMEViz: a web service for site of metabolism estimating and visualizing.
    Shen Q; Zheng M; Lu J; Luo C; Zhu W; Chen K; Luo X; Jiang H
    Protein Pept Lett; 2012 Sep; 19(9):905-9. PubMed ID: 22894162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using GastroPlus.
    Heikkinen AT; Baneyx G; Caruso A; Parrott N
    Eur J Pharm Sci; 2012 Sep; 47(2):375-86. PubMed ID: 22759901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist.
    Cruciani G; Carosati E; De Boeck B; Ethirajulu K; Mackie C; Howe T; Vianello R
    J Med Chem; 2005 Nov; 48(22):6970-9. PubMed ID: 16250655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reaction phenotyping: advances in the experimental strategies used to characterize the contribution of drug-metabolizing enzymes.
    Zientek MA; Youdim K
    Drug Metab Dispos; 2015 Jan; 43(1):163-81. PubMed ID: 25297949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.